Hematologic Cancers

FDA Approves Tagraxofusp, First Approved Treatment for a Rare, Aggressive Hematologic Cancer

FDA Approves Tagraxofusp, First Approved Treatment for a Rare, Aggressive Hematologic Cancer

By

FDA grants approval to tagraxofusp-erzs (Elzonris), a first treatment for blastic plasmacytoid dentritic cell neoplasm and the first therapy to target CD123.

Mini-Pools of IVIG Just as Effective as Standard IVIG in Pediatric Immune Thrombocytopenia

Mini-Pools of IVIG Just as Effective as Standard IVIG in Pediatric Immune Thrombocytopenia

By

Intravenous immunoglobulin G with plasma from fewer blood donations provides sufficient therapeutic effect for pediatric patients with ITP.

Apixaban Significantly Lowers Risk of Venous Thromboembolism in High-Risk Patients

Apixaban Significantly Lowers Risk of Venous Thromboembolism in High-Risk Patients

By

A clinical trial demonstrates that apixaban effectively decreases risk of VTE in patients with cancer; however, risk of major bleeding episodes may be higher.

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

By

The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.

FDA Grants Approval to New Treatment for Acute Myeloid Leukemia

FDA Grants Approval to New Treatment for Acute Myeloid Leukemia

Randomized clinical trial showed significant improvement in overall survival with glasdegib.

Azacytidine, Nivolumab Combination Provides Safe, Effective Balance in Relapsed/Refractory AML

Azacytidine, Nivolumab Combination Provides Safe, Effective Balance in Relapsed/Refractory AML

By

Researchers investigated the safety and efficacy of combination therapy with azacytidine and nivolumab for relapsed/refractory AML.

Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia

Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia

By

Researchers reviewed cancer incidence in patients with Diamond-Blackfan anemia.

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

By

A meta-analysis of 14 randomized, controlled trials was conducted to determine if combining G-CSF with intensified chemotherapy improved overall survival.

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

By

A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.

Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study

Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study

By

A prospective cohort study from Denmark investigated the link between maternal hormonal contraception use before — more than 3 months and within 3 months — and during pregnancy and risk of leukemia in their children.

Risk of Relapse Up for Young Adults With Leukemia

Risk of Relapse Up for Young Adults With Leukemia

Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

By

A retrospective follow-up study demonstrates that tandem autologous-allogeneic is safe for standard and high-risk multiple myeloma. However, benefits do not extend to patients with ultra-high-risk disease and those with disease progression after autologous HCT.

Belly Fat Is a Better Risk Calculator for Blood Cancers Than BMI

Belly Fat Is a Better Risk Calculator for Blood Cancers Than BMI

By

BMI often relies on self-reported weight and height values, and therefore may be a less accurate predictor of cancer risk than alternative body composition measurements.

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

By

A substudy of a multinational study sought to determine the risk to ovarian function with ABVD, AVD, and BEACOPP regimens on ovarian function in women with Hodgkin lymphoma.

Infections in Primary Immune Thrombocytopenia Associated With Low Platelet Count

Infections in Primary Immune Thrombocytopenia Associated With Low Platelet Count

By

A retrospective study of platelet- and infection-related data from patients with ITP revealed the influence platelet levels have on infections as well as efficacy of transfusions.

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22-directed cytotoxin, has been approved for adult patients who have had at least two prior therapies for the disease.

Fostamatinib Appears Effective for Immune Thrombocytopenia

Fostamatinib Appears Effective for Immune Thrombocytopenia

Researchers found that stable responses occurred in 18 percent of patients on fostamatinib, versus 2 percent on placebo.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

By

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

By

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

By

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

Pre-HSCT Conditioning May Improve Physical Functioning in Hematologic Cancers

Pre-HSCT Conditioning May Improve Physical Functioning in Hematologic Cancers

By

In this retrospective study, researchers assessed the outcomes of 88 patients with hematologic disease who underwent HSCT.

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

By

Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

By

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

By

Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

By

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

By

In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

By

A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

By

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Long-Term Azithromycin May Increase Risk of Relapse of Blood Cancers After HSCT

Long-Term Azithromycin May Increase Risk of Relapse of Blood Cancers After HSCT

By

US FDA issues a recommendation on use of azithromycin in patients with hematologic malignancies who have undergone HSCT.

Effect of HSCT on HRQOL and Posttraumatic Stress in Young Adult Cancer Survivors

Effect of HSCT on HRQOL and Posttraumatic Stress in Young Adult Cancer Survivors

By

Study sought to determine the health-related QOL and posttraumatic stress symptoms in adolescent and young adult cancer survivors post-HSCT compared with their healthy peers.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs